Anuncio • Jun 02
Medifast, Inc. Announces Resignation of Jason L. Groves from Chief Legal Officer & Corporate Secretary, Effective May 29, 2026 Medifast, Inc. reported that Jason L. Groves, Esq., the Chief Legal Officer & Corporate Secretary of Medifast, Inc., tendered his resignation from the Company. The employment relationship terminated effective May 29, 2026. Mr. Groves' departure was not the result of any disagreement with the Company nor any issue related to the Company's operations, policies or practices. In connection with Mr. Groves' departure, the Company has commenced a search for a permanent replacement. Anuncio • May 06
Medifast, Inc. Provides Earnings Guidance for the Second Quarter of 2026 Medifast, Inc. provided earnings guidance for the second quarter of 2026. The company expects second quarter 2026 revenue to be in the range of $60 million to $80 million and second quarter 2026 loss per share to be in the range of $0.50 to $1.00. Anuncio • Apr 21
Medifast, Inc. to Report Q1, 2026 Results on May 04, 2026 Medifast, Inc. announced that they will report Q1, 2026 results After-Market on May 04, 2026 Anuncio • Apr 07
Medifast, Inc., Annual General Meeting, May 19, 2026 Medifast, Inc., Annual General Meeting, May 19, 2026. Location: 1000 aliceanna street, maryland 21202, baltimore United States Anuncio • Mar 20
Jeffrey Brown and Michael Hoer Does Not Stand for Reelection as Directors of Medifast, Inc Medifast, Inc. announced the company's Board of Directors has agreed to nominate Parsa Kiai and Jeff Rose from Steamboat Capital Partners LLC as independent director candidates to stand for election at the company’s 2026 Annual Meeting of Stockholders, which is provisionally scheduled for May 19, 2026. These nominations are pursuant to a Cooperation Agreement entered into between the company and Steamboat Capital, which beneficially owns above 5% of the company’s outstanding shares. The Board of Directors has determined that Medifast’s directors Jeffrey Brown and Michael Hoer will not stand for reelection. Medifast Chairman & Chief Executive Officer Dan Chard will continue in his current role, and as previously announced, will step down as CEO on June 1, 2026, while remaining Chairman. Nicholas Johnson, President of Medifast, is expected to succeed Dan Chard as CEO following his departure. Anuncio • Feb 20
Medifast Announces OPTAVIA's Comprehensive Metabolic Health System Is Available for Reimbursement on Select Insurance Plans Using Health Savings Accounts and Flexible Spending Accounts Medifast announced that OPTAVIA’s comprehensive metabolic health system is available for reimbursement on select insurance plans using Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). OPTAVIA clients may be able to save up to 40% on program costs by working with their medical provider and insurance administrator to use pre-tax medical funds, offering accessibility for those prioritizing their metabolic health. OPTAVIA is designed to address these challenges head-on, combining a science-backed system with coaching to guide clients toward improvements in their metabolic health, targeting the root cause of metabolic dysfunction. OPTAVIA’s approach is rooted in our breakthrough science, Metabolic Synchronization™, which resets the body’s metabolism through healthy, quality weight loss, targeting visceral fat reduction, preserving lean mass and protecting healthy muscle. Using the science of Metabolic Synchronization, Medifast plans to launch a new system in 2026 featuring products that incorporate clinically studied ingredients designed to further support metabolic health, marking the next step in the company’s ongoing commitment to providing solutions that adapt to every stage of the health journey. In a clinical study, 98% of lean mass was retained and individuals experienced a reduction of 14% visceral adiposity [visceral fat] on the Optimal Weight 5 & 1 Plan® at 16 weeks. Anuncio • Feb 18
Medifast, Inc. Provides Earnings Guidance for the First Quarter of 2026 and Fiscal Year 2026 Medifast, Inc. provided earnings guidance for the first quarter of 2026 and fiscal year 2026. The company expects first quarter 2026 revenue to be in the range of $65 million to $80 million and first quarter 2026 loss per share to range from $0.15 to $0.70.
The company expects full year 2026 revenue to be in the range of $270 million to $300 million and full year 2026 loss per share to range from $1.55 to $2.75. Anuncio • Feb 04
Medifast, Inc. to Report Q4, 2025 Results on Feb 17, 2026 Medifast, Inc. announced that they will report Q4, 2025 results After-Market on Feb 17, 2026 Anuncio • Jan 31
Medifast, Inc. Declares Dividend, Payable on March 31, 2026 Medifast, Inc. announced a dividend of $1.00. The ex-dividend date is February 13, 2026, with a record date of February 18, 2026. The payment date for the dividend is scheduled for March 31, 2026. Anuncio • Nov 14
Medifast Scientific & Clinical Affairs Team Showcases New Research in Metabolic Health At ObesityWeek Conference Medifast continues to lead the charge in addressing the growing health crisis of metabolic dysfunction by unveiling new research findings during ObesityWeek. Hosted by The Obesity Society in Atlanta, Georgia November 4-7, 2025, the annual conference for obesity researchers and clinicians centers on the latest developments in evidence-based obesity science: cutting-edge basic and clinical research, state-of-the-art obesity treatment and prevention and the latest efforts in advocacy and public policy. With a proud legacy of more than 40 years of clinical and scientific innovation, the Medifast Scientific and Clinical Affairs (S&CA) team continues to play a pivotal role in driving forward the understanding and management of metabolic health challenges. As part of the company's recently announced strategic transformation centered on metabolic health, Medifast's S&CA team presented two research studies that underscore its commitment to tackling metabolic dysfunction and promoting holistic health: "Mind the Plateau: Addressing Long-Term Weight Loss with Anti-Obesity Medications" - This study evaluates the long-term effects of GLP-1 medications, noting a weight loss plateau after 96 weeks of treatment with the highest dosage (15mg of Tirzepatide). It also reports a significant rebound in energy intake following medication discontinuation, leading to weight regain. Specifically, poor sleep quality increased the odds of obesity by 1.8 times and diabetes by 2.5 times over an average 12-year follow-up period. These findingsunderscore that sleep health should be considered alongside diet and physical activity as a core pillar of preventive health, healthy aging and optimal metabolic health. This research reinforces Medifast's broader business strategy introduced in October 2025 with the launch of Metabolic Synchronization™?, a breakthrough science that reverses metabolic dysfunction through a targeted reset of the body's metabolism. In addition to the conference presentations, Medifast Scientific Advisory Board member Dr. Jessica Unick, a Professor at Brown University and Senior Research Scientist at The Miriam Hospital's weight Control and Diabetes Research Center, co-authored a study alongside Medifast S&CA team members that explored predictors of weight loss. The study emphasized the importance of adherence and early intervention as key predictors of meaningful weight loss. With 30+ peer-reviewed studies, 70+ presentations and more than 40 years of clinical heritage, Medifast continues to set benchmarks for scientific rigor and innovation in the health and wellness industry. The S&CA team leads by example, leveraging their expertise at the crossroads of science and wellness to drive transformative change and support individuals on their wellness journeys. Anuncio • Nov 04
Medifast, Inc. Provides Earnings Guidance for the Fourth Quarter 2025 Medifast, Inc. provided earnings guidance for the fourth quarter 2025. The company expects fourth quarter 2025 revenue to be in the range of $65 million to $80 million and fourth quarter 2025 diluted loss per share to be in the range of $0.70 to $1.25. Anuncio • Oct 27
Medifast, Inc. Announces Strategic Shift to Metabolic Health with the Introduction of Metabolic Synchronization Medifast, Inc. announced a strategic transformation, unveiling a new focus on holistic metabolic health. The company introduced Metabolic Synchronization™? -- a breakthrough science that reverses metabolic dysfunction with a targeted reset of the body's metabolism. Research shows the company's comprehensive system activates strong and targeted fat burn to improve metabolic health by reducing bad visceral fat, preserving lean mass and protecting muscle. This approach results in quality weight loss that goes beyond the scale, ultimately empowering individuals to reach their health goals. With nine in ten U.S. adults metabolically unhealthy, the country is facing a health crisis. Metabolic health -- often misunderstood or overlooked -- refers to the body's ability to efficiently convert food into energy, regulate critical body functions and maintain internal balance. Metabolic dysfunction is a state that can oftenently slip in and can put the body's metabolic processes under strain, cascading into some of today's most serious health challenges. Building on its legacy of transforming lives, Medifast is advancing its approach with Metabolic Synchronization™®?, a breakthrough science that reversales metabolic dysfunction with a targeted restart of the body's metabolism. This new science leverages years of clinical evidence to deliver results beyond the number on the scale. The first step of Metabolic Synchronization is quality weight loss. Recent breakthrough research shows the company's comprehensive system activate strong and targeted fat burn, driving measurable improvements in overall metabolic health and body composition through three key mechanisms: Burn: Targets visceral fat -- the bad fat stored around organs and muscles -- achieving a 14% reduction in vascular fat in just 16 weeks. Preserve: Helps retain 98% of lean mass, supporting strength, energy and mobility during weight loss. Protect: Supports healthy muscle to help restore the body's natural ability to improve an active metabolism, optimize energy use and regulate body weight. By focusing on the root causes of metabolic dysfunction, Medifast is unlocking new opportunities to reach and empower individuals at every stage of their health journey. For people utilizing weight loss medications, Medifast's programs provide complementary solutions to enhance metabolic function and overall health. For those pursuing a medication-free approach, the company's science-backed system offers an effective alternative, delivering measurable results through its holistic focus on metabolic health. Backed by Science, Driven by Innovation and Connection: With over 40 years of industry leadership, supported by 30+ peer-reviewed publications and clinical studies, Medifast remains committed to advancing science and innovation. The company's structured programs remain integral to this evolution, providing clients with a trusted foundation for metabolic health. Medifast also continues to stand apart with its human-centered approach. Clients who work with a personal coach experience 10 times greater weight loss and 17 times greater fat loss than those pursuing self-directed approaches+. Looking ahead, the company plans to launch new products using the science of metabolic synchronization in 2026, incorporating next-generation ingredients that further enhance metabolic health. Anuncio • Oct 21
Medifast, Inc. to Report Q3, 2025 Results on Nov 03, 2025 Medifast, Inc. announced that they will report Q3, 2025 results After-Market on Nov 03, 2025 Anuncio • Aug 05
Medifast, Inc. Provides Earnings Guidance for the Third Quarter 2025 Medifast, Inc. provided earnings guidance for the third quarter 2025. For the quarter, the company expects revenue to be in the range of $70 million to $90 million and diluted income/(loss) per share to be in the range of ($0.60) to $0.00. Anuncio • Jul 22
Medifast, Inc. to Report Q2, 2025 Results on Aug 04, 2025 Medifast, Inc. announced that they will report Q2, 2025 results After-Market on Aug 04, 2025 Anuncio • May 01
Medifast, Inc., Annual General Meeting, Jun 18, 2025 Medifast, Inc., Annual General Meeting, Jun 18, 2025. Location: 200 international drive, baltimore, maryland 21202, United States Anuncio • Apr 29
Medifast, Inc. Provides Earnings Guidance for the Second Quarter 2025 Medifast, Inc. provided earnings guidance for the second quarter 2025. The company expects second quarter 2025 revenue to be in the range of $85 million to $105 million and second quarter 2025 loss per share to be in the range of $0.00 to $0.55. Anuncio • Apr 15
Medifast, Inc. to Report Q1, 2025 Results on Apr 28, 2025 Medifast, Inc. announced that they will report Q1, 2025 results After-Market on Apr 28, 2025 Anuncio • Feb 19
Medifast, Inc. Provides Earnings Guidance for the First Quarter of 2025 Medifast, Inc. provided earnings guidance for the first quarter of 2025. The company expects first quarter 2025 revenue to be in the range of $100 million to $120 million and first quarter 2025 EPS to range from a loss of $0.50 per diluted share to $0.00 per diluted share. Anuncio • Feb 05
Medifast, Inc. to Report Q4, 2024 Results on Feb 18, 2025 Medifast, Inc. announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Feb 18, 2025 Anuncio • Jan 07
Medifast Introduces New High-Protein Product Line OPTAVIA ASCEND for GLP-1 Users & Those Looking for Help to Keep Weight Off Medifast announced OPTAVIA ASCEND -- a new product line of high-protein, fiber-rich mini meals as well as a daily nutrient pack. These products are featured in two new science-backed nutrition plans designed for people on GLP-1 medications and those looking for help to keep weight off. The mini meals provide essential nutrients to promote muscle health, digestive health and bone health, and combined with the new plans and OPTAVIA's holistic offer, fill a critical gap in the weight management market. Medifast's launches OPTAVIA ASCEND - a new product line of high -protein, fiber-rich mini meal as well as a daily nutrient packs. These products are featured in a new science-backed nutrition plans Designed for people on GLP- 1 medications. GLP-1 medications are revolutionizing weight loss, but challenges remain. Studies show that two-thirds of weight lost on GLP-1 medications is typically regained within 12 months of stopping treatment, with cardiometabolic benefits often reversing as well. Additionally, muscle loss on GLP-1 medications can equal up to a decade worth of naturally occurring muscle loss within just 12-18 months, according to a recent scientific manuscript by Medifast published in Current Developments in Nutrition1. These findings highlight the importance of combining GLP-1 medications with proper nutrition and lifestyle habits, such as eating a protein-rich diet and incorporating regular resistance training to support skeletal muscle and metabolic health. Reported Earnings • Nov 05
Third quarter 2024 earnings released: EPS: US$0.10 (vs US$2.12 in 3Q 2023) Third quarter 2024 results: EPS: US$0.10 (down from US$2.12 in 3Q 2023). Revenue: US$140.2m (down 41% from 3Q 2023). Net income: US$1.13m (down 95% from 3Q 2023). Profit margin: 0.8% (down from 9.8% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue is expected to decline by 13% p.a. on average during the next 3 years, while revenues in the Personal Products industry in Europe are expected to grow by 4.7%. Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings. Anuncio • Nov 05
Medifast, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024 Medifast, Inc. provided earnings guidance for the fourth quarter of 2024. The Company expected revenue to be in the range of $100 million to $120 million and fourth quarter 2024 diluted loss per share to be in the range of $0.10 to $0.65. The EPS range excludes any gains or losses from changes in the market price of the company’s LifeMD common stock investment. Anuncio • Oct 22
Medifast, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Medifast, Inc. announced that they will report Q3, 2024 results After-Market on Nov 04, 2024 Reported Earnings • Aug 06
Second quarter 2024 earnings released: US$0.75 loss per share (vs US$2.78 profit in 2Q 2023) Second quarter 2024 results: US$0.75 loss per share (down from US$2.78 profit in 2Q 2023). Revenue: US$168.6m (down 43% from 2Q 2023). Net loss: US$8.15m (down 127% from profit in 2Q 2023). Revenue is expected to decline by 20% p.a. on average during the next 2 years, while revenues in the Personal Products industry in Europe are expected to grow by 5.2%. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 55% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Jul 31
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €19.65, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 22x in the Personal Products industry in Europe. Total loss to shareholders of 91% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.89 per share. Anuncio • Jul 23
Medifast, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Medifast, Inc. announced that they will report Q2, 2024 results After-Market on Aug 05, 2024 Valuation Update With 7 Day Price Move • Jul 08
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €16.72, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 23x in the Personal Products industry in Europe. Total loss to shareholders of 92% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.18 per share. Buy Or Sell Opportunity • Jul 01
Now 45% overvalued Over the last 90 days, the stock has fallen 37% to €20.15. The fair value is estimated to be €13.90, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.8% over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to decline by 27% in a year. Earnings are forecast to decline by 83% in the next year. Buy Or Sell Opportunity • Jun 21
Now 24% overvalued Over the last 90 days, the stock has fallen 41% to €18.45. The fair value is estimated to be €14.83, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.8% over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to decline by 27% in a year. Earnings are forecast to decline by 83% in the next year. Buy Or Sell Opportunity • Jun 13
Now 22% overvalued Over the last 90 days, the stock has fallen 42% to €19.08. The fair value is estimated to be €15.67, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.8% over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to decline by 27% in a year. Earnings are forecast to decline by 83% in the next year. Valuation Update With 7 Day Price Move • May 31
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €23.79, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 21x in the Personal Products industry in Europe. Total loss to shareholders of 90% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €17.42 per share. Buy Or Sell Opportunity • May 23
Now 20% overvalued Over the last 90 days, the stock has fallen 39% to €22.60. The fair value is estimated to be €18.78, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 5.8% over the last 3 years. Earnings per share has declined by 12%. Revenue is forecast to decline by 28% in a year. Earnings are forecast to decline by 82% in the next year. Valuation Update With 7 Day Price Move • May 06
Investor sentiment deteriorates as stock falls 26% After last week's 26% share price decline to €24.17, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 20x in the Personal Products industry in Europe. Total loss to shareholders of 88% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €17.08 per share. New Risk • Apr 30
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 76% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 76% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Significant insider selling over the past 3 months (€99k sold). Reported Earnings • Apr 30
First quarter 2024 earnings released: EPS: US$0.76 (vs US$3.68 in 1Q 2023) First quarter 2024 results: EPS: US$0.76 (down from US$3.68 in 1Q 2023). Revenue: US$174.7m (down 50% from 1Q 2023). Net income: US$8.32m (down 79% from 1Q 2023). Profit margin: 4.8% (down from 12% in 1Q 2023). The decrease in margin was driven by lower revenue. Revenue is expected to decline by 17% p.a. on average during the next 2 years, while revenues in the Personal Products industry in Europe are expected to grow by 5.2%. Over the last 3 years on average, earnings per share has fallen by 12% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings. Anuncio • Apr 30
Medifast, Inc. Provides Earnings Guidance for the Second Quarter of 2024 Medifast, Inc. provided earnings guidance for the second Quarter of 2024. The company expects second quarter 2024 revenue to be in the range of $150 million to $170 million and second quarter 2024 diluted EPS to be in the range of $0.05 to $0.40. The EPS range excludes the costs related to the initiation of the LifeMD collaboration and any gains or losses from changes in the market price of the company’s LifeMD common stock investment. Anuncio • Apr 16
Medifast, Inc. to Report Q1, 2024 Results on Apr 29, 2024 Medifast, Inc. announced that they will report Q1, 2024 results After-Market on Apr 29, 2024 Valuation Update With 7 Day Price Move • Apr 06
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €29.37, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 20x in the Personal Products industry in Europe. Total loss to shareholders of 82% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €33.71 per share. Recent Insider Transactions • Mar 14
Independent Director recently sold €99k worth of stock On the 8th of March, Scott Schlackman sold around 3k shares on-market at roughly €36.05 per share. This transaction amounted to 37% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €453k more than they bought in the last 12 months. Valuation Update With 7 Day Price Move • Feb 27
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to €37.22, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 19x in the Personal Products industry in Europe. Total loss to shareholders of 81% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €34.22 per share. New Risk • Feb 22
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 63% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 63% per year for the foreseeable future. Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change). New Risk • Feb 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Feb 21
Full year 2023 earnings released: EPS: US$9.13 (vs US$12.82 in FY 2022) Full year 2023 results: EPS: US$9.13 (down from US$12.82 in FY 2022). Revenue: US$1.07b (down 33% from FY 2022). Net income: US$99.4m (down 31% from FY 2022). Profit margin: 9.3% (up from 9.0% in FY 2022). The increase in margin was driven by lower expenses. Revenue is expected to decline by 19% p.a. on average during the next 2 years, while revenues in the Personal Products industry in Europe are expected to grow by 5.3%. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings. Anuncio • Feb 21
Medifast Provides Earnings Guidance for the First Quarter of 2024 Medifast provided earnings guidance for the first quarter of 2024. For the period, the company expects revenue to be in the range of $155 million to $175 million and diluted EPS to be in the range of $0.25 to $0.95. Anuncio • Feb 07
Medifast, Inc. to Report Q4, 2023 Results on Feb 20, 2024 Medifast, Inc. announced that they will report Q4, 2023 results After-Market on Feb 20, 2024 Anuncio • Nov 07
Medifast, Inc. Provides Earnings Guidance for the Full Year 2023 Medifast, Inc. provided earnings guidance for the full year 2023. For the year, the company expects revenue to be in the range of $1,050 million to $1,070 million and full-year 2023 diluted EPS to be in the range of $8.65to $9.55. Reported Earnings • Nov 07
Third quarter 2023 earnings released: EPS: US$2.12 (vs US$3.30 in 3Q 2022) Third quarter 2023 results: EPS: US$2.12 (down from US$3.30 in 3Q 2022). Revenue: US$235.9m (down 40% from 3Q 2022). Net income: US$23.1m (down 36% from 3Q 2022). Profit margin: 9.8% (in line with 3Q 2022). Revenue is expected to decline by 16% p.a. on average during the next 3 years, while revenues in the Personal Products industry in Europe are expected to grow by 5.3%. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. New Risk • Oct 31
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €392k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 25% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Significant insider selling over the past 3 months (€392k sold). Anuncio • Oct 24
Medifast, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Medifast, Inc. announced that they will report Q3, 2023 results After-Market on Nov 06, 2023 Anuncio • Sep 14
Medifast, Inc. Announces Optavia Active Now Available Medifast announced its OPTAVIA ACTIVE line is now available to Customers, following a successful pre-launch to independent OPTAVIA Coaches in July 2023. The line, exclusively available on OPTAVIA.com when sign up to connect with an OPTAVIA Coach, includes OPTAVIA ACTIVE Essential Amino Acid (EAA) Blend and OPTAVIA ACTIVE Whey Protein, with additional products expected to be rolled out next year. The new line encourages the Habit of Healthy Motion, a key component of any health and wellness journey, and is scientifically designed to support muscle health. With more than one billion adults across the world not meeting the recommended guidelines for physical activity, the World Health Organization developed a global action plan to reduce physical inactivity by 15% by 20302. It's time to put the power of Community to work toward that goal. The new products work within existing OPTAVIA plans for those looking to achieve or maintain their optimal weight but also are a great solution for people wanting to enhance their health and wellbeing through movement. OPTAVIA ACTIVE products are backed by science, made with no colors, flavors or sweeteners from artificial sources and are Informed Sport certified - a global standard in sports nutrition quality control that ensures its certified products contain no banned substances. Through the app, users have access to more than 8,000 on-demand, guided workouts across 15+ class categories and 60+ fitness and wellness programs as well as a global community feed where they will find further advice and support. The company's proprietary OPTAVIA app has also been updated to include features supporting the new ACTIVE platform, including an integrated motion tracker. The app is designed to help OPTAVIA Customers track and document their health journey and offers a convenient resource to guide Customers on their paths to a healthier lifestyle. Now through October 31, 2023, Customers can save $10.00 on the purchase of up to three OPTAVIA ACTive products, for a maximum of $30.00 savings, in addition to $7.00 flat rate shipping with the purchase of two or moreOPTAVIA ACTIVE products. Anuncio • Sep 08
Medifast, Inc. Declares Quarterly Cash Dividend, Payable on November 7, 2023 Medifast, Inc. announced that its Board of Directors has declared a $1.65 quarterly cash dividend to its stockholders. The quarterly cash dividend is payable on November 7, 2023, to stockholders of record as of the close of business on September 19, 2023. Anuncio • Aug 09
Medifast, Inc. Provides Earnings Guidance for the Third Quarter 2023 Medifast, Inc. provided earnings guidance for the third quarter 2023. For the period, the company expects revenue to be in the range of $220 million to $240 million and third quarter 2023 diluted EPS to be in the range of $0.71 to $1.32. Reported Earnings • Aug 08
Second quarter 2023 earnings released: EPS: US$2.78 (vs US$3.45 in 2Q 2022) Second quarter 2023 results: EPS: US$2.78 (down from US$3.45 in 2Q 2022). Revenue: US$296.2m (down 35% from 2Q 2022). Net income: US$30.3m (down 23% from 2Q 2022). Profit margin: 10% (up from 8.6% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is expected to decline by 24% p.a. on average during the next 2 years, while revenues in the Personal Products industry in Europe are expected to grow by 5.1%. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Anuncio • Jul 28
Medifast Unveils New Product Line, Optavia Active Medifast unveiled a new product line, OPTAVIA ACTIVE. The line includes premium exercise supplements and protein powders, OPTAVIA ACTive Essential Amino Acid (EAAs) Blend and OPTAVIA ACTIVE Whey Protein, with other products expected to be rolled out next year. Both are designed to help new and existing Customers of all fitness levels optimize their motion habits. OPTAVIA ACTIVE marks an inflection point for the company, as it targets new Customer segments and triples its total addressable market by entering the sports nutrition category - a $30 billion market. Formulated to work with or without OPTAVIA nutrition plans and guided by Coach support, OPTAVIA ACTives is backed by science, made with no colors, flavors or sweeteners from artificial sources and is Informed Sport certified -- a global standard in sports nutrition quality control that ensures its certified products contain no banned substances. OPTAVIA A ACTIVE EAAs contain a clinically studied blend of eighessential amino acids, including an imprpressive 3.5 grams of leucine per serving, specifically designed to help activate muscle protein synthesis -- the natural process where protein is produced to repair or build new muscle. OPTAVIA ACTive Whey Protein contains 24 grams of high-quality, complete protein per serving, and when paired with a healthy diet and exercise plan, can help build muscle and strength. As pt ofof this new healthy motion program, the company has partnered with Aaptiv, a leading fitness app, to provide on-demand, guided workouts for its Community. Anuncio • Jul 25
Medifast, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Medifast, Inc. announced that they will report Q2, 2023 results After-Market on Aug 07, 2023 Buying Opportunity • Jul 18
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 5.4%. The fair value is estimated to be €104, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 22%. Revenue is forecast to decline by 23% in a year. Earnings is forecast to decline by 37% in the next year. Anuncio • Jun 16
Medifast, Inc. Declares Quarterly Cash Dividend, Payable on August 8, 2023 Medifast, Inc. announced that its Board of Directors has declared a $1.65 quarterly cash dividend to its stockholders. The quarterly cash dividend of $1.65 per share is payable on August 8, 2023, to stockholders of record as of the close of business on June 27, 2023. Anuncio • May 26
Medifast, Inc., Annual General Meeting, Jun 14, 2023 Medifast, Inc., Annual General Meeting, Jun 14, 2023, at 16:30 US Eastern Standard Time. Location: The Four Seasons Baltimore, 200 International Drive, Baltimore Maryland United States Agenda: To elect seven nominees to the Board of Directors to serve for a one-year term expiring in 2024; to ratify the appointment of RSM US LLP as the independent registered public accounting firm of the company for the fiscal year ending December 31, 2023; to approve, on an advisory basis, the compensation of the company's named executive officers; to approve, on an advisory basis, the frequency of the advisory vote on executive compensation; and to transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof. Reported Earnings • May 03
First quarter 2023 earnings released: EPS: US$3.68 (vs US$3.62 in 1Q 2022) First quarter 2023 results: EPS: US$3.68. Revenue: US$349.0m (down 16% from 1Q 2022). Net income: US$40.0m (down 4.3% from 1Q 2022). Profit margin: 12% (up from 10.0% in 1Q 2022). The increase in margin was driven by lower expenses. Revenue is expected to decline by 13% p.a. on average during the next 2 years, while revenues in the Personal Products industry in Europe are expected to grow by 5.3%. Reported Earnings • Feb 22
Full year 2022 earnings released: EPS: US$12.82 (vs US$14.01 in FY 2021) Full year 2022 results: EPS: US$12.82 (down from US$14.01 in FY 2021). Revenue: US$1.60b (up 4.8% from FY 2021). Net income: US$143.6m (down 13% from FY 2021). Profit margin: 9.0% (down from 11% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is expected to decline by 10% p.a. on average during the next 2 years, while revenues in the Personal Products industry in Europe are expected to grow by 4.9%. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Anuncio • Feb 08
Medifast, Inc. to Report Q4, 2022 Results on Feb 21, 2023 Medifast, Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Feb 21, 2023 Upcoming Dividend • Dec 12
Upcoming dividend of US$1.64 per share Eligible shareholders must have bought the stock before 19 December 2022. Payment date: 07 February 2023. Payout ratio is a comfortable 48% and this is well supported by cash flows. Trailing yield: 5.4%. Within top quartile of German dividend payers (4.9%). Higher than average of industry peers (2.0%). Anuncio • Dec 09
Medifast, Inc. Announces Quarterly Dividend, Payable on February 7, 2023 Medifast, Inc. announced that its Board of Directors has declared a $1.64 quarterly cash dividend to its stockholders. The quarterly cash dividend of $1.64 per share is payable on February 7, 2023, to stockholders of record as of the close of business on December 20, 2022. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 11 experienced directors. 1 highly experienced director. Independent Director Michael Hoer was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Buying Opportunity • Nov 05
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 22%. The fair value is estimated to be €140, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 34% over the last 3 years. Earnings per share has grown by 31%. Revenue is forecast to decline by 2.4% in 2 years. Earnings is forecast to decline by 3.0% in the next 2 years. Anuncio • Nov 04
Medifast, Inc. Revises Earnings Guidance for the Year 2022 Medifast, Inc. revised earnings guidance for the year 2022. The company now anticipates that full-year 2022 revenue to be in the range of $1.51 billion to $1.59 billion, down from the previously announced range of $1.58 billion to $1.66 billion that was previously disclosed. Anuncio • Oct 21
Medifast, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Medifast, Inc. announced that they will report Q3, 2022 results After-Market on Nov 03, 2022 Upcoming Dividend • Sep 12
Upcoming dividend of US$1.64 per share Eligible shareholders must have bought the stock before 19 September 2022. Payment date: 08 November 2022. Payout ratio is a comfortable 45% but the company is paying out more than the cash it is generating. Trailing yield: 5.2%. Within top quartile of German dividend payers (4.8%). Higher than average of industry peers (2.2%). Anuncio • Sep 09
Medifast Announces Quarterly Dividend, Payable on November 8, 2022 Medifast, Inc. announced that its Board of Directors has declared a $1.64 quarterly cash dividend to its stockholders. The quarterly cash dividend of $1.64 per share is payable on November 8, 2022, to stockholders of record as of the close of business on September 20, 2022. Recent Insider Transactions • Aug 13
Lead Independent Director recently bought €487k worth of stock On the 9th of August, Jeffrey Brown bought around 4k shares on-market at roughly €124 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €365k more in shares than they have sold in the last 12 months. Valuation Update With 7 Day Price Move • Aug 10
Investor sentiment deteriorated over the past week After last week's 24% share price decline to €129, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 25x in the Personal Products industry in Europe. Total returns to shareholders of 59% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €142 per share. Reported Earnings • Aug 04
Second quarter 2022 earnings released: EPS: US$3.45 (vs US$4.00 in 2Q 2021) Second quarter 2022 results: EPS: US$3.45 (down from US$4.00 in 2Q 2021). Revenue: US$453.3m (up 15% from 2Q 2021). Net income: US$39.1m (down 17% from 2Q 2021). Profit margin: 8.6% (down from 12% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 16%, compared to a 7.8% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth. Anuncio • Aug 04
Medifast, Inc. Revises Earnings Guidance for the Full-Year of 2022 Medifast, Inc. revised earnings guidance for the full-year of 2022. The Company expects full-year 2022 revenue to be in the range of $1.58 billion to $1.66 billion, down from the previously announced range of $1.78 billion to $1.84 billion. Anuncio • Jul 22
Medifast Announces New Scientific Advisory Board Appointments Medifast OPTAVIA®, announced the addition of three new members to its long-standing Scientific Advisory Board: Dr. Nikhil Dhurandhar, Dr. Graham Thomas and Dr. Jessica Unick. Medifast'sScientific Advisory Board is now comprised of seven internationally recognized experts who provide objective insights to guide the company in making informed decisions based on the latest scientific developments in health and wellness. The cross-disciplinary panel was established in 2008 in service of the company's commitment to providing an evidence-based, safe and effective health and wellness program that meets consumer needs. Dr. Dhurandhar's 38 years of experience as a physician and nutritional biochemist has included the use of lifestyle interventions in his treatment of over 15,000 patients with obesity. Dr. Thomas' research focuses on the use of technology for the assessment and treatment of health behaviors, which he applies when developing AI-powered behavioral intervention research and digital health technologies. Dr. Unick's weight loss research focuses on adapting behavioral interventions for early non-responders and the impact of physical activity. Anuncio • Jul 21
Medifast, Inc. to Report Q2, 2022 Results on Aug 03, 2022 Medifast, Inc. announced that they will report Q2, 2022 results After-Market on Aug 03, 2022 Anuncio • Jun 26
Medifast, Inc.(NYSE:MED) dropped from Russell 2000 Dynamic Index Medifast, Inc.(NYSE:MED) dropped from Russell 2000 Dynamic Index Upcoming Dividend • Jun 20
Upcoming dividend of US$1.64 per share Eligible shareholders must have bought the stock before 27 June 2022. Payment date: 08 August 2022. Payout ratio is a comfortable 42% but the company is paying out more than the cash it is generating. Trailing yield: 3.7%. Lower than top quartile of German dividend payers (4.5%). Higher than average of industry peers (2.4%). Anuncio • Jun 17
Medifast, Inc. Announces Quarterly Dividend, Payable on August 8, 2022 Medifast, Inc. announced that its Board of Directors has declared a $1.64 quarterly cash dividend to its stockholders. The quarterly cash dividend of $1.64 per share is payable on August 8, 2022 to stockholders of record as of the close of business on June 28, 2022. Recent Insider Transactions • May 12
Executive Chairman & CEO recently bought €75k worth of stock On the 5th of May, Daniel Chard bought around 431 shares on-market at roughly €174 per share. This was the largest purchase by an insider in the last 3 months. Daniel has been a buyer over the last 12 months, purchasing a net total of €188k worth in shares. Reported Earnings • May 04
First quarter 2022 earnings released: EPS: US$3.62 (vs US$3.49 in 1Q 2021) First quarter 2022 results: EPS: US$3.62 (up from US$3.49 in 1Q 2021). Revenue: US$417.6m (up 23% from 1Q 2021). Net income: US$41.8m (up 1.7% from 1Q 2021). Profit margin: 10.0% (down from 12% in 1Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 15%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Anuncio • May 03
Medifast, Inc. Revises Earnings Guidance for the Full-Year of 2022 Medifast, Inc. revised earnings guidance for the full-year of 2022. For the year, the company expects revenue to be in the range of $1.78 billion to $1.84 billion, up from the previously announced guidance range of $1.72 billion to $1.79 billion. EPS to be in the range of $14.60 to $16.05, up from the previously announced guidance range of $14.50 to $16.00. The revised full-year 2022 earnings guidance assumes a 24.25% to 25.25% effective tax rate. The earnings guidance excludes a one-time second quarter 2022 donation to the Ukrainian refugees.